» Articles » PMID: 23125893

Hypoxia-induced Oxidative Stress in Ischemic Retinopathy

Overview
Publisher Wiley
Date 2012 Nov 6
PMID 23125893
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidative stress plays a crucial role in the pathogenesis of retinal ischemia/hypoxia, a complication of ocular diseases such as diabetic retinopathy (DR) and retinopathy of prematurity (ROP). Oxidative stress refers to the imbalance between the production of reactive oxygen species (ROS) and the ability to scavenge these ROS by endogenous antioxidative systems. Free radicals and ROS are implicated in the irreversible damage to cell membrane, DNA, and other cellular structures by oxidizing lipids, proteins, and nucleic acids. Anti-oxidants that can inhibit the oxidative processes can protect retinal cells from ischemic/hypoxic insults. In particular, treatment using anti-oxidants such as vitamin E and lutein, inhibition of nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) or related signaling pathways, and administration of catalase and superoxide dismutase (SOD) are possible therapeutic regimens for DR, ROP, and other retinal ischemic diseases. The role of oxidative stress in the pathogenesis of DR and ROP as well as the underlying mechanisms involved in the hypoxia/ischemia-induced oxidative damage is discussed. The information provided will be beneficial in understanding the underlying mechanisms involved in the pathogenesis of the diseases as well as in developing effective therapeutic interventions to treat oxidative stress-induced damages.

Citing Articles

Peripheral Retinal Ischemia and Secondary Neovascular Glaucoma after Cerclage for Retinal Detachment: A Case Report.

Menna F, Menke M, Tschopp M Case Rep Ophthalmol. 2025; 16(1):86-94.

PMID: 39981539 PMC: 11842065. DOI: 10.1159/000543239.


The Role of Dietary Antioxidants, Food Supplements and Functional Foods for Energy Enhancement in Healthcare Professionals.

Kalogerakou T, Antoniadou M Antioxidants (Basel). 2025; 13(12.

PMID: 39765836 PMC: 11672929. DOI: 10.3390/antiox13121508.


Enhancing Late Retinopathy of Prematurity Outcomes with Fresh Bone Marrow Mononuclear Cells and Melatonin Combination Therapy.

Mirnia K, Bitaraf M, Namakin K, Azimzadeh A, Tanourlouee S, Zolbin M Stem Cell Rev Rep. 2024; 21(2):466-476.

PMID: 39503829 DOI: 10.1007/s12015-024-10819-y.


Addressing retinal hypoxia: pathophysiology, therapeutic innovations, and future prospects.

Gnanasambandam B, Prince J, Limaye S, Moran E, Lee B, Huynh J Ther Adv Ophthalmol. 2024; 16:25158414241280187.

PMID: 39376745 PMC: 11457288. DOI: 10.1177/25158414241280187.


Nutraceuticals for Diabetic Retinopathy: Recent Advances and Novel Delivery Systems.

Ye X, Fung N, Lam W, Lo A Nutrients. 2024; 16(11).

PMID: 38892648 PMC: 11174689. DOI: 10.3390/nu16111715.


References
1.
Li S, Lo A . Lutein protects RGC-5 cells against hypoxia and oxidative stress. Int J Mol Sci. 2010; 11(5):2109-17. PMC: 2885097. DOI: 10.3390/ijms11052109. View

2.
Chance B, Sies H, Boveris A . Hydroperoxide metabolism in mammalian organs. Physiol Rev. 1979; 59(3):527-605. DOI: 10.1152/physrev.1979.59.3.527. View

3.
Radi R, Cassina A, Hodara R . Nitric oxide and peroxynitrite interactions with mitochondria. Biol Chem. 2002; 383(3-4):401-9. DOI: 10.1515/BC.2002.044. View

4.
Kowluru R, Kanwar M, Chan P, Zhang J . Inhibition of retinopathy and retinal metabolic abnormalities in diabetic rats with AREDS-based micronutrients. Arch Ophthalmol. 2008; 126(9):1266-72. PMC: 10280296. DOI: 10.1001/archopht.126.9.1266. View

5.
Rivera J, Sapieha P, Joyal J, Duhamel F, Shao Z, Sitaras N . Understanding retinopathy of prematurity: update on pathogenesis. Neonatology. 2011; 100(4):343-53. DOI: 10.1159/000330174. View